<DOC>
	<DOC>NCT01598038</DOC>
	<brief_summary>The investigators hypothesize everolimus toxicities are linked to pharmacokinetic variabilities of everolimus. Thus, early detection of clinical or biological risk factors will lead to personalized dosage treatment and permit a better tolerance without altering efficacy.</brief_summary>
	<brief_title>Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1. Patients aged â‰¥ 18 yearold. 2. Histologically documented renal cell carcinoma whatever the type. 3. One or two prior therapy with cytokines and/or VEFGligand inhibitors are permitted. 4. Patients with an indication to receive everolimus treatment 5. Patients able and willing to give written informed consent, before the first screening procedure. 1. Patients currently receiving chemotherapy or immunotherapy 2. Prior treatment with temsirolimus 3. Contraindication in everolimus : Hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients. Patients with severe hepatic impairment (ChildPugh class C) Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicinal product. 4. Pregnant or breastfeeding women 5. Patients unwilling to or unable to comply with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>renal</keyword>
	<keyword>Afinitor</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>